Chief Executive Officer, Immix Biopharma
Appears in 1 story
Driving NXC-201 toward a Biologics License Application after the Phase 2 readout
Immix Biopharma reported Thursday that 19 of 20 patients in its NEXICART-2 Phase 2 trial reached complete remission with NXC-201, a one-time CAR-T cell therapy for AL amyloidosis. The 95% complete response rate is up from 75% in an earlier readout, and all four patients with minimal-residual-disease-negative status have now converted to complete responses.
Updated May 21
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
